Primary Osteoarthritis Market Share

Global Primary Osteoarthritis Market Overview

Primary Osteoarthritis Market Size was valued at USD 5.63 Billion in 2023. The Global Primary Osteoarthritis industry is projected to grow from USD 6.93 Billion in 2024 to USD 12.56 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.42% during the forecast period (2024 - 2032).Arthritis refers to inflammation of the joint, accompanied by joint pain and stiffness. It may be acute or chronic. Obesity, infections, crystal deposition, joint injury, and old age are some of the common causes associated with arthritis. Osteoarthritis and rheumatoid arthritis are two common types of arthritis. Osteoarthritis is a chronic disease, which affects joints, including ligament, cartilage, joint lining, and underlying bones. This disease results in joint pain and stiffness due to the breakdown of cartilage. It is also known as Degenerative Joint Disease (DJD). Primary osteoarthritis and secondary osteoarthritis are the two major forms of osteoarthritis. Primary osteoarthritis results from abnormal stress on weight-bearing joints. This is prevalent mostly in the aging population.

Physical therapy, occupational therapy, chronic pain class, and braces are some of the therapies associated with osteoarthritis. Moreover, osteoarthritis treatment includes surgical procedures such as lubrication injections, cortisone shots, and joint replacement. Rising incidences of surgeries, increasing technological advancements, increasing number of pipeline drugs, and rising awareness about health care are some of the key factors driving the growth of the osteoarthritis market. In addition, rising disposable income in developing countries is also fueling the growth of the osteoarthritis market.

However, stringent regulatory policies and less adoption of osteoarthritis treatment are restraining the growth of the osteoarthritis market. In addition, side effects associated with osteoarthritis medications are also impeding the growth of Primary Osteoarthritis Market.

Intended Audience

• Primary Osteoarthritis Drug Suppliers


• Primary Osteoarthritis Drug Manufacturers


• Research and Development (R&D) Companies


• Medical Research Laboratories


• Academic Medical Institutes and Universities

Primary Osteoarthritis Market Segment Insights

The primary osteoarthritis market is segmented on the basis of type, diagnosis, treatment, and end-users.

Primary Osteoarthritis Type Insights

On the basis of the type, the market is segmented into knee osteoarthritis, hand osteoarthritis, neck osteoarthritis, hip osteoarthritis, wrist osteoarthritis, spinal osteoarthritis, shoulder osteoarthritis, and others

Primary Osteoarthritis Diagnosis Insights

On the basis of the diagnosis, the Primary Osteoarthritis Market is segmented into imaging, joint fluid analysis, and others. The imaging segment is further classified into divided X-rays, Magnetic resonance imaging (MRI), and others.

Primary Osteoarthritis Treatment Insights

On the basis of the treatment, the Primary Osteoarthritis Market is segmented into medication, therapies, surgery, and others. The medication segment can be classified into analgesics and non-steroidal anti-inflammatory drugs. The analgesics segment is further classified as acetaminophen, duloxetine, and others. The non-steroidal anti-inflammatory drugs can be further classified into aspirin, ibuprofen, naproxen sodium/ naproxen, and others.

Primary Osteoarthritis End-user Insights

On the basis of the end-user, the market is segmented into hospitals & clinics, medical institutes, research organization, and others.

Primary Osteoarthritis Regional Insights      

The primary osteoarthritis market consists of countries namely America, Europe, Asia Pacific, and the Middle East and Africa.

Currently, North America dominates the osteoarthritis market, followed by Europe. This is due to the rising prevalence of osteoarthritis diseases and growing geriatric population in these regions. In addition, increasing access to health care insurance, especially in the U.S., is also influencing the growth of the Primary Osteoarthritis Market.

The European primary osteoarthritis market is expected to witness rapid growth owing to the high investment in various private and government-funded research and development programs in the region and increased spending on pharmaceutical and biotechnology industry development.

Asia is expected to be the fastest growing market in the next five years. This is due to the rising healthcare infrastructure and increasing government initiatives for better health care facilities in this region. Moreover, a large patient population base is driving the growth of the Primary Osteoarthritis Market in this region.  

The Middle East region is expected to grow at a faster rate due to the factors such as the extensive development of healthcare infrastructure and growing emphasis on research and development in the healthcare sector.

Key Players

The emergence of new and cost-effective medication options for the treatment of osteoarthritis could open up new opportunities for new players in the osteoarthritis market. In addition, emerging markets, such as India and China, could also open new opportunities for new players. Increasing number of strategic alliances between various companies, rising number of product innovations, and increase in the number of clinical trials for pain reliving biologic drugs, such as anti-NGFs, are among the recent market trends in the Primary Osteoarthritis Market.

Some of key the players in the primary osteoarthritis market are

• Abbott Laboratories (U.S.)


• Johnson & Johnson Limited (U.S.)


• Novartis AG (Switerzland)


• Pfizer, Inc. (U.S.)


• Eli Lilly and Company (U.S.)


• Abiogen Pharma (Italy)


• Ampio pharmaceuticals (U.S.),


• BioDelivery Sciences International (U.S.)


• CrystalGenomics (South Korea)


• Daiichi Sankyo (Japan)


• Eli Lilly (U.S.)


• Horizon Pharma (Republic of Ireland)


• Iroko Pharmaceuticals (U.S.)


• Merck & Co. Ltd (U.S.)


• Nuvo Research (U.S.)


• Regeneus (Australia)


• Sanofi (France),


• SantoSolve (U.S.), 


• Smith & Nephew (UK)


• Winston Pharmaceuticals (India)